Algert Global LLC Allakos Inc. Transaction History

Algert Global LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.18 $99,209 - $183,422	-57,680 Reduced 66.15%	29,520 $81,000
Q3 2023 Nov 13, 2023	SELL	$2.13 - $5.55 $1.07 Million - $2.78 Million	-501,274 Reduced 85.18%	87,200 $198,000
Q2 2023 Aug 14, 2023	BUY	$3.6 - $5.25 $846,684 - $1.23 Million	235,190 Added 66.57%	588,474 $2.57 Million
Q1 2023 May 12, 2023	BUY	$4.3 - $8.27 $470,351 - $904,605	109,384 Added 44.85%	353,284 $1.57 Million
Q4 2022 Feb 13, 2023	BUY	$5.66 - $8.42 $1.38 Million - $2.05 Million	243,900 New	243,900 $2.05 Million
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $22,760 - $297,851	-2,662 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $203,722 - $293,964	2,662 New	2,662 $282,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $81.3M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.